Triple-negative breast cancer (TNBC) refers to cancers that are low in expression of the
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Triple‐negative breast cancer (TNBC) is characterized by the absence of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It …

Triple‑negative breast cancer (TNBC) is a highly heterogeneous and aggressive
malignancy. Due to the absence of estrogen receptors and progesterone receptors and the …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally
associated with a high risk of recurrence and poor prognosis. Our understanding of the …